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Biomarkers are important for guiding the clinical and 
therapeutic management of all phases of rheumatoid arthritis 
because they can help to predict disease development in 
subjects at risk, improve diagnosis by closing the serological 
gap, provide prognostic information that is useful for making 
therapeutic choices and assessing treatment responses and 
outcomes, and allow disease activity and progression to 
be monitored. Various biomarkers can be used to identify 
subjects susceptible to the disease and those with pre-clinical 
rheumatoid arthritis before the onset of symptoms such as 
rheumatoid factor and anti-citrullinated protein antibodies. 
They can be correlated with a risk of developing rheumatoid 
arthritis and can predict more bone erosions and severe 
disease progression. Biomarkers such as the erythrocyte 
sedimentation rate and C-reactive protein levels provide 
information about disease activity, while predictive biomarkers 
allow clinicians to assess the probability of a treatment 
response before starting a particular therapy particularly in the 
era of biological drugs. This move from traditional approaches 
to patient stratiﬁcation and targeted treatment should greatly 
improve patient care and reduce medical costs.
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R heumatoid arthritis (RA), which has an estimated world-wide prevalence in adults of 0.8% and more frequently 
affects females, is characterized by joint inflammation and 
destruction and gives rise to functional limitations, working 
disability, and a poor quality of life 
[1]. Its etiology is still unknown, 
and there is increasing interest in 
studying the biomarkers involved 
in different stages of this pathogenetically complex disease [2]. 
A biomarker is an objectively measurable and assessable 
indicator of normal biological or pathogenic processes or 
pharmacological responses to a therapeutic intervention [3], 
which can be derived from genetic polymorphisms, autoanti-
body profiles, cytokine levels, or clinical parameters. They are 
divided into three categories distinguished on the basis of their 
parameters, clinical usefulness, and relation with the patho-
logical process [4]. This last category is further subdivided into 
descriptive biomarkers (which reflect disease status but are not 
directly involved in its pathogenesis and provide only limited 
diagnostic and prognostic information), and mechanistic bio-
markers, which are predictively and pharmacodynamically use-
ful as they indicate a dysregulation of the molecular pathways 
directly involved in disease pathogenesis [5].
Biomarkers are important for guiding the clinical and 
therapeutic management of all phases of RA because they can 
help to predict disease development in subjects at risk, improve 
diagnosis by closing the serological gap, provide prognostic 
information that is useful for making therapeutic choices and 
assessing treatment responses and outcomes, and allow disease 
activity and progression to be monitored [5].
DIAGNOSTIC AND PROGNOSTIC BIOMARKERS
Various biomarkers can be used to identify individuals sus-
ceptible to the disease and those with pre-clinical RA before 
the onset of symptoms. The detection of autoantibodies such 
as rheumatoid factor (RF) and anticitrullinated protein anti-
bodies (ACPAs) forms part of the European League Against 
Rheumatism/American College of Rheumatology (EULAR/
ACR) diagnostic criteria [6] and can guide the choice of 
treatments aimed at preventing or slowing the development 
of symptomatic RA [5]. High RF titers correlate with the risk 
of developing RA, which may 
increase by as much as 26 times 
if they are >100 IU/ml [7], and 
the presence of the immuno-
globulin A (IgA) isotype is associated with extra-articular 
manifestations [8]. Patients with RF usually develop a more 
aggressive disease and experience more severe functional 
impairment. However, RF positivity alone is not sufficient 
for diagnosis [9] as 15% of the healthy population may 
have low titers, and this proportion increases with age [10]. 
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Furthermore, RF is also found in patients with other auto- 
immune rheumatological or infectious diseases [10,11]. 
ACPAs develop long before clinical symptoms are noted, 
and RA patients are divided into ACPA-positive and ACPA-
negative [12,13] with characteristics that similar during the 
early stages of the disease. However, over time, those who 
are in the ACPA-positive group develop more bone erosions 
and experience more severe disease progression [13,14]. 
Environmental factors, especially smoking, can increase the 
risk of developing ACPAs, and ACPA positivity increases the 
risk of cardiac disease [15]. 
A new set of anti-carbamylated protein antibodies, which 
can be found in ACPA-negative RA patients, has been identified 
as a potential means of making an early diagnosis and assessing 
prognosis [16]. They predict joint damage regardless of the pres-
ence of ACPAs (which are also known to predict joint damage), 
as well as the development of early RA [16]. 
Finally, it has been found that the serum titers of anti-
Porphyromonas gingivalis antibodies may correlate with the 
diagnosis and/or disease activity of RA [17].
MONITORING BIOMARKERS 
Biomarkers, such as the erythrocyte sedimentation rate (ESR) 
and C-reactive protein (CRP) levels, provide information about 
disease activity but are not sufficiently predictive alone to be 
used for purposes of treatment decision making [6,18]. The 
“treat to target” recommendations include three composite 
scores for the monitoring disease evolution [19]:
t 28-joint disease activity score (DAS28)
t Simple disease activity index (SDAI) 
t Clinical disease activity index (CDAI) 
However, as these scores have the disadvantage of the degree 
of subjectivity of some of their criteria, a multi-biomarker dis-
ease activity test has been developed to improve monitoring 
with mild, moderate and severe disease activity being indicated 
by scores of 1–28, 29–43, and ≥ 44, respectively [20]. 
BIOMARKERS PREDICTING TREATMENT RESPONSE
Predictive biomarkers allow clinicians to assess the probability 
of a treatment response before starting a particular therapy [21]. 
Major therapeutic advances 
have been made since the in- 
troduction of biological agents 
targeting pivotal mediators in 
the inflammatory process by inhibiting tumor necrosis fac-
tor alpha (TNF-α inhibitors [TNFIs]), IL-1 (anakinra), IL-6 
(tocilizumab), T-cell co-stimulation (CD80/CD86, abatacept), 
or B-lymphocyte antigen (CD20, rituximab), but 30–40% of 
the patients receiving biological agents do not respond to the 
prescribed agent [22]. 
The current clinical strategy is to prescribe a biological agent 
after the failure of initial treatment with methotrexate, often 
combined with low-dose glucocorticoids. If the decrease in 
disease activity induced by the first biological agent (usually 
a TNFI) becomes insufficient (usually after 3–6 months), the 
patient is switched to another biological agent and the process 
of evaluating the clinical response is resumed. However, this is 
very inefficient because the patient may have uncontrolled dis-
ease leading to irreversible (and expensive) joint damage [22]. 
A way to predict responses to specific treatments is therefore 
needed to optimise the treatment choices for each patient [23].
BIOMARKERS AND ANTI-TNF DRUGS
Many pharmacogenetic studies have so far failed to identify any 
gene polymorphisms associated with a response to TNFIs [21]. 
One meta-analysis investigating the role of the TNF-α promoter 
-308 G/A polymorphism in the response to anti-TNF therapy 
showed that patients with the G allele responded better, odds 
ration (OR) = 1.87, 95% confidence interval (CI) 1.26–2.79, 
and a sub-analysis of RA patients confirmed this result [24].
A recent systematic bioinformatics analysis evaluating the 
effect of infliximab on refractory RA found that five genes 
(FKBP1A, FGF12, ANO1, LRRC31, and AKR1D1) in periph-
eral blood were associated with efficacy [25]. This model has 
been shown to have good predictive power in prospective, 
randomized studies, with an area under the receiver operating 
characteristic curve of 0.963 and 1.000. It has also been found 
to be usable in the early phase of treatment (week 2) as a means 
of predicting response by week 14 (AUC = 1.000). These data 
suggest that the model is useful for efficiently predicting the 
response to infliximab in RA patients [25].
Data from the British Society for Rheumatology Biologics 
Registry (BSRBR) suggest that a poor response to anti-TNF 
drugs is associated with a high level of baseline disability, 
that not administering non-steroidal anti-inflammatory 
drugs or concomitant methotrexate reduces the likelihood of 
a response (particularly to etanercept), that smokers are less 
likely to respond to infliximab, and that women are less likely 
to achieve remission [26]. The Danish DANBIO registry has 
reported that an older age, prednisolone co-therapy, and poor 
functional status each predict a poorer response to the first anti-
TNF treatment [27], whereas a Gruppo Italiano per lo studio 
dell’early arthritis (GISEA) 
study identified RF negativity, 
a lower Health Assessment 
Questionnaire (HAQ) score, an 
age of < 53 years, and male gender as independent predictors 
of remission at 6 months [28]. The Lombardy Rheumatology 
Network registry showed that the relative risk (RR) of remis-
sion was associated with male gender, and that a lower RR of 
Predictive biomarkers allow clinicians 
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that is similar to that reported in clinical trials. Anti-CCPA 
positivity was associated with a better response to abatacept 
regardless of disease activity [36].
Furthermore, the large, international, non-interventional 
ACTION study of a cohort of patients with moderate-severe 
RA who started intravenous abatacept in Canada and Europe 
between May 2008 and January 2011 showed that anti-CCPA 
positivity (hazard ratio [HR] 0.55, 95%CI 0.40–0.75, P  <  0.001), 
failure on < 2 previous anti-TNF agents (HR 0.71, 95%CI 
0.56–0.90, P = 0.005) vs. ≥ 2, and cardiovascular comorbidity 
at the time of starting abatacept (HR 0.48, 95%CI 0.28–0.83, 
P  =  0.009) were associated with a lower risk of discontinuation, 
and that patients in Greece and Italy were less likely to discon-
tinue abatacept than those in Germany and Canada (Greece 
HR 0.30, 95%CI 0.16–0.58 and Italy HR 0.50, 95%CI 0.33–0.76; 
Canada HR 1.04, 95%CI 0.78–1.40; P  < 0.001 vs. Germany) 
The differences in the retention rates may reflect differences 
in the countries’ healthcare systems [37]. 
In brief, the real-world prognostic factors for abatacept 
retention include anti-CCPA positivity and fewer prior anti-
TNF failures, but not RF positivity. 
BIOMARKERS AND TOCILIZUMAB 
A multi-center ambispective observational study of 126 RA 
patients treated with tocilizumab as first- or second-line bio-
logical treatment found that the predictors 
increasing the likelihood of clinical remis-
sion after 3 months included a baseline 
ESR of > 30 mm/h, baseline CRP levels of 
> 10 mg/L, and the presence of extra-articular disease mani-
festations, whereas the factors decreasing the likelihood con-
sisted of higher hemoglobin concentrations, a higher baseline 
DAS28-ESR score, and a higher number of previous DMARDs 
and biological therapies [38]. There was no relationship with 
neutrophil counts or RF or anti-CCPA positivity.
FUTURE BIOMARKERS
The use and continued refinement of large-scale genomic, 
transcriptomic, proteomic, and other “omic” technologies have 
generated large amounts of multivariate data that require robust 
bioinformatic analyses, and the candidate biomarkers identified 
using these data require rigorous validation. Only a few have 
been adopted in clinical practice. Those that are only detect-
able in tissue are less useful than those obtained non-invasively 
[4] and, as RA and other rheumatic diseases are not driven by 
single gene mutations, single or multiple gene biomarkers are 
not predictively useful. 
Nevertheless, considerable progress has been made by 
evaluating synovial tissue obtained by means of blind needle 
biopsies, visually guided arthroscopic biopsies and ultrasound-
guided biopsies. The information acquired concerning the 
remission was associated with previous treatment with > 3 
disease-modifying anti-rheumatic drugs (DMARDs), a high 
ESR, Steinbrocker’s functional class III/IV, and a high tender 
joint count. Futhermore, the same study showed that a 12 
month EULAR non-response was observed in 153/821 patients 
(18.6%) and was associated with a higher baseline HAQ score 
and previous treatment with > 3 DMARDs (and corticosteroid 
> 5 mg/day [29]. BSRBR data showed that, after 6 months of 
anti-TNF therapy (mainly with infliximab and etanercept), 
RF-positive patients had a DAS28 improvement of 2.43 com-
pared with 3.03 in RF-negative patients (P = 0.02), and the 
equivalent data for ACPA status were 2.40 in ACPA-positive 
patients, and 2.90 in ACPA-negative patients (P = 0.02) [30]. 
BIOMARKERS AND RITUXIMAB
Studies have found that RF-positive patients respond better 
to rituximab than RF-negative patients, with ACR20 response 
values of 54% vs. 41% and 54% vs. 48%, respectively, although 
a third found no difference between the two sub-groups [31]. 
Dass and colleagues [32] also found that baseline positivity for 
circulating ACPA, particularly immunoglobulin M (IgM), and 
high levels of infiltrating CD20+ and CD79a+CD20− B-cells in 
a rheumatoid synovium predicted an incomplete response after 
B-cell depletion. A large-scale Italian study comprised of 110 
patients found that a lower HAQ score, fewer failures on pre-
vious anti-TNF agents before rituximab, 
and RF (but not anti-CCP) positivity 
were associated with an ACR50 response, 
but only RF positivity correlated with a 
EULAR moderate/good response at both univariate and mul-
tivariate analysis [33]. 
The predictors of a better response to rituximab include 
lower levels of type I interferon (IFN-γ), lower serum levels 
of B-cell activating factor (BAFF) or B lymphocyte stimulator 
(BLyS), and a favorable Fcγ receptor III (FcγRIII) genotype 
[34]. The study also investigated polymorphisms in the pro-
moter region of the BLyS gene, and found that the TTTT BLyS 
promoter haplotype seemed to be significantly associated with 
a response to rituximab only in the subset of patients who were 
seropositive for RF and/or ACPAs and had previously failed on 
another anti-TNF drug [34]. Finally, the same authors showed 
that the 158VV Fcgamma receptor 3A genotype is associated 
with a response to rituximab [35].
BIOMARKERS AND ABATACEPT
The Orencia and Rheumatoid Arthritis (ORA) prospective 
registry of 1003 RA patients promoted by the French Society 
of Rheumatology has shown that a EULAR response is asso-
ciated with anti-CCPA positivity (OR = 1.9, 95%CI 1.2–2.9, 
P = 0.007) but not RF positivity (OR = 1.0, 95%CI 0.6–1.6, 
P = 0.9) [36]. Anti-CCPA positivity is also significantly associ-
ated with a higher 6 month abatacept retention rate, a finding 
The use of biomarkers should 
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possibility of stratifying patients on the basis of histological 
patterns may prove to be predictive [39]. It has also been recog-
nised that the microbiome plays an important role in rheumatic 
diseases such as RA, and the microbial signatures identified 
by means of next-generation sequencing may lead to a new 
promising class of biomarkers [4]. 
Among miRNAs, miR-146a is expressed by activated T cells 
(in which it suppresses apoptosis and IL-2 production), and its 
expression in the synovium is associated with increased RA 
disease activity. Another candidate miRNA biomarker is miR-
155, which induces the development of Th1 and Th17 cells, 
and whose expression is increased in the peripheral blood 
mononuclear cells of RA patients [4].
CONCLUSIONS
Patients at risk for RA can undergo biomarker tests to detect 
the earliest stage of disease and begin treatment to prevent its 
development. The use of predictive biomarkers allows new 
therapies to be targeted to the patients most likely to respond, 
and pharmacodynamic biomarkers can be used to monitor 
their actual response. This move from traditional approaches 
to patient stratification and targeted treatment should greatly 
improve patient care and reduce medical costs. 
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In North America, tuberculosis incidence is now very low and 
risk to healthcare workers has fallen. Indeed, recent cohort 
data question routine annual tuberculosis screening in this 
context. Mullie and co-authors compared the cost-effectiveness 
of three potential strategies for ongoing screening of North 
American healthcare workers at risk of exposure. The analysis 
did not evaluate the cost-effectiveness of screening at hiring, 
and considered only workers with negative baseline tests. 
Over 20 years, annual screening with the tuberculin skin tests 
(TST) yielded an expected 2.68 active tuberculosis cases per 
1000 workers, versus 2.83 for targeted screening and 3.03 for 
post-exposure screening only. In all cases, annual screening 
was associated with poorer quality-adjusted survival, that 
is, lost quality-adjusted life years, compared to targeted or 
post-exposure screening only. The annual TST screening 
strategy yielded an incremental cost estimate of $1,717,539 
per additional case prevented versus targeted TST screening, 
which in turn cost an incremental $426,678 per additional case 
prevented versus post-exposure TST screening only. With the 
alternate “higher-risk” scenario, the annual TST strategy costs 
an estimated $426,678 per additional case prevented versus 
the targeted TST strategy, which costs an estimated $52,552 per 
additional case prevented versus post-exposure TST screening 
only. In all cases, QuantiFERON®-TB (QFT) manufactured 
by Cellestis Limited, Carnegie, Victoria, Australia was more 
expensive than TST, with no, or limited, added beneﬁt. 
Sensitivity analysis suggested that, even with limited exposure 
recognition, annual screening was poorly cost-effective.
BMC Ned 2017; 15: 104
Eitan Israeli
Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-
effectiveness analysis
Capsule
Current pharmacologic treatment of the neonatal abstinence 
syndrome with morphine is associated with a lengthy duration 
of therapy and hospitalization. Buprenorphine may be more 
effective than morphine for this indication. In this single-site, 
double-blind, double-dummy clinical trial, Kraft and colleagues 
randomly assigned 63 term infants (≥ 37 weeks of gestation) 
who had been exposed to opioids in utero and who had 
signs of the neonatal abstinence syndrome to receive either 
sublingual buprenorphine or oral morphine. Infants with 
symptoms that were not controlled with the maximum dose 
of opioid were treated with adjunctive phenobarbital. The 
primary endpoint was the duration of treatment for symptoms 
of neonatal opioid withdrawal. Secondary clinical end points 
were the length of hospital stay, the percentage of infants 
who required supplemental treatment with phenobarbital, 
and safety. The median duration of treatment was signiﬁcantly 
shorter with buprenorphine than with morphine (15 days vs. 
28 days), as was the median length of hospital stay (21 days 
vs. 33 days) (P < 0.001 for both comparisons). Adjunctive 
phenobarbital was administered in 5 of 33 infants (15%) in 
the buprenorphine group and in 7 of 30 infants (23%) in the 
morphine group (P = 0.36). Rates of adverse events were 
similar in the two groups.
NEJM 2017; 376: 2341
Eitan Israeli
Capsule
Buprenorphine for the treatment of the neonatal abstinence syndrome
“Of all the preposterous assumptions of humanity over humanity, nothing exceeds most of the 
criticisms made on the habits of the poor by the well-housed, well-warmed, and well-fed”
Herman Melville (1819–1891) American novelist, short story writer, and poet of the American Renaissance period
